Journal
CURRENT CARDIOLOGY REPORTS
Volume 17, Issue 8, Pages -Publisher
SPRINGER
DOI: 10.1007/s11886-015-0618-4
Keywords
Anticoagulants; Atrial fibrillation; Cost-effectiveness analysis; Bleeding; Stroke
Categories
Funding
- Heart & Stroke Foundation (H&SF) of Canada Distinguished Clinical Scientist Award
Ask authors/readers for more resources
Recently, novel oral anticoagulants (NOACs) have been approved for stroke prevention in patients with atrial fibrillation (AF). Although these agents overcome some disadvantages of warfarin, they are associated with increased costs. In this review, we will provide an overview of the cost-effectiveness of NOACs for stroke prevention in AF. Our comments and conclusions are limited to studies directly comparing all available NOACs within the same framework. The available cost-effectiveness analyses suggest that NOACs are cost-effective compared to warfarin, with apixaban likely being most favorable. However, significant limitations in these models are present and should be appreciated when interpreting their results.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available